Research programme: RNAi-based hepatitis C therapy - Nucleonics

Drug Profile

Research programme: RNAi-based hepatitis C therapy - Nucleonics

Latest Information Update: 20 Jan 2011

Price : $50

At a glance

  • Originator Nucleonics
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 26 Nov 2007 This programme is still in active development
  • 09 Feb 2005 Nucleonics and Apath LLC have entered into a non-exclusive licensing agreement for Apath technology related to the 3' non-translated region of the hepatitis C viral genome
  • 03 Dec 2003 Preclinical trials in Hepatitis C treatment in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top